NCT06516445 2024-07-24
SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC
Huazhong University of Science and Technology
Phase 2 Recruiting
Clinical Trials
11 trialsNCT04715633 2024-07-09
PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal Cancer
Sun Yat-sen University
Phase 2 Active not recruiting
NCT06423937 2024-05-21
Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer
Fudan University
Phase 2 Not yet recruiting
NCT06148402 2024-05-13
Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Recruiting
NCT06176885 2023-12-27
FOBECAMS
Jinhua Central Hospital
Phase 2 Recruiting
NCT05202314 2023-02-21
NACSOC-02
Beijing Chao Yang Hospital
Phase NA Recruiting
NCT04866862 2022-07-25
Fruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT05193292 2022-01-14
Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer
Fudan University
Phase 2 Unknown
NCT04298320 2020-03-16
A Trial of SHR-1210 in Combination With AIN457 in Patients With MSS CRC（SHR-1210-AIN457）
Harbin Medical University
Phase 1/2 Unknown
NCT03645876 2019-05-10
SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Terminated
NCT03912857 2019-04-16
Camrelizumab(SHR-1210) Combined With Apatinib in the Treatment of Advanced Metastatic Colorectal Cancer
Sun Yat-sen University
Phase 2 Unknown